Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maxime, Berquier"'
Autor:
Maxime Berquier, Lucie Cherel, Dominique Clerc Renaud, Carole Hospital Gustems, Anne Wallart Brejaud, Ibrahim Yakoub-Agha, David Beauvais
Publikováno v:
Bulletin du Cancer. 108:S39-S44
In the attempt to harmonize practices and to create a national CAR T-cells patient follow-up care logbook, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) worked on the design of a common national care logbook du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d244f8f46b6ca7f19441c09f45780cc
https://doi.org/10.1016/j.bulcan.2021.02.012
https://doi.org/10.1016/j.bulcan.2021.02.012
Autor:
Ibrahim Yakoub-Agha, Anne Wallart Brejaud, Isabelle Fournier, Christelle Andrianne, Corinne Courbon, Josiane Delorme, Sarah Bole, Clotilde Aubrun, Maxime Berquier, Damien Lacroix, Ghislaine François, David Beauvais, Marlene Vercasson, Marie-France Jaivenois, Isabelle Mussot, Alexis Caulier, Laetitia Le Bars
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
Bulletin du Cancer, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
Bulletin du Cancer, John Libbey Eurotext, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
Bulletin du Cancer, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
International audience; In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03db488bc89c986082e1ae6c920d6813
https://hal.archives-ouvertes.fr/hal-03492618
https://hal.archives-ouvertes.fr/hal-03492618
Autor:
Maxime, Berquier, Lucie, Cherel, Dominique, Clerc Renaud, Carole, Hospital Gustems, Anne, Wallart Brejaud, Ibrahim, Yakoub-Agha, David, Beauvais
Publikováno v:
Bulletin du cancer. 108(12S)
In the attempt to harmonize practices and to create a national CAR T-cells patient follow-up care logbook, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) worked on the design of a common national care logbook du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9940ddd3dfa57f3daf3bb3fe5951bae9
https://pubmed.ncbi.nlm.nih.gov/33992416
https://pubmed.ncbi.nlm.nih.gov/33992416
Autor:
David, Beauvais, Christelle, Andrianne, Clotilde, Aubrun, Maxime, Berquier, Sarah, Bole, Alexis, Caulier, Corinne, Courbon, Josiane, Delorme, Isabelle, Fournier, Ghislaine, François, Marie-France, Jaivenois, Laëtitia, Le Bars, Isabelle, Mussot, Marlène, Vercasson, Anne, Wallart Brejaud, Ibrahim, Yakoub-Agha, Damien, Lacroix
Publikováno v:
Bulletin du cancer. 107(12S)
In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation centers still need to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e61b94787e7da9887d1a4e0c8c8bd5f9
https://pubmed.ncbi.nlm.nih.gov/32891406
https://pubmed.ncbi.nlm.nih.gov/32891406
Autor:
Maxime Berquier
Publikováno v:
Hématologie. 24:97-100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04e0186ef8c9a6daae1451845c0aecad
https://doi.org/10.1684/hma.2018.1333
https://doi.org/10.1684/hma.2018.1333
Autor:
Driss Chaoui, Vincent Camus, Jean-Pierre Marolleau, Maxime Berquier, Véronique Meignin, Géraldine Salmeron, Bénédicte Deau-Fischer, Rene-Olivier Casasnovas, Luc Mathieu Fornecker, Anne Quinquenel, Celia Salanoubat, Frédérique Kuhnowski, Véronique Morel, Gandhi Damaj, Roberta Di Blasi, Pierre Feugier, Catherine Thieblemont, Sophie Bernard, Elie Azoulay, Michael Darmon, Jérôme Paillassa, Guillaume Cartron, Sophie Rigaudeau, David Sibon, Emmanuel Gyan, Vincent Delwail, Sylvie Chevret, Corinne Haioun, Jean Valère Malfuson
Publikováno v:
Blood
Blood, 2019, 134 (1), ⟨10.1182/blood-2019-129532⟩
Blood, 2019, 134 (1), ⟨10.1182/blood-2019-129532⟩
Introduction: The autologous anti-CD19 chimeric antigen receptor (CD19 CAR) T-cells demonstrated significant clinical benefits and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), with an ORR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f53f8606865a2ab250fc9ef0b5e7b9
https://doi.org/10.1182/blood-2019-129532
https://doi.org/10.1182/blood-2019-129532